Paolo Abada, Ph.D.
Affiliations: | 2005 | University of Southern California, Los Angeles, CA, United States |
Area:
Molecular Biology, Biochemistry, Public HealthGoogle:
"Paolo Abada"Cross-listing: PHTree
Parents
Sign in to add mentor| Paula M. Cannon | grad student | 2005 | USC | |
| (The human immunodeficiency virus type-2 envelope glycoprotein and viral particle assembly.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Llovet JM, Singal AG, Villanueva A, et al. (2022) Prognostic and predictive factors in patients with advanced HCC and elevated alpha-fetoprotein treated with ramucirumab in two randomized Phase III trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Kudo M, Finn RS, Morimoto M, et al. (2021) Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Liver Cancer. 10: 451-460 |
| Galle PR, Kudo M, Llovet JM, et al. (2021) Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease etiology. Liver International : Official Journal of the International Association For the Study of the Liver |
| Kudo M, Ikeda M, Galle PR, et al. (2021) Ramucirumab in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: outcomes by treatment-emergent ascites. Hepatology Research : the Official Journal of the Japan Society of Hepatology |
| Kudo M, Galle PR, Brandi G, et al. (2021) Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. Jhep Reports : Innovation in Hepatology. 3: 100215 |
| Reig M, Galle PR, Kudo M, et al. (2020) Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. Liver International : Official Journal of the International Association For the Study of the Liver |
| Yen CJ, Kudo M, Lim HY, et al. (2020) Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies. Liver Cancer. 9: 440-454 |
| Zhu AX, Nipp RD, Finn RS, et al. (2020) Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials. Esmo Open. 5 |
| Galle PR, Kudo M, Llovet JM, et al. (2020) Impact of baseline hepatitis B viremia and management on outcomes in patients (Pts) with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Outcomes from REACH-2. Journal of Clinical Oncology. 38: 569-569 |
| Kudo M, Finn RS, Morimoto M, et al. (2020) Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): Pooled results from two phase III studies (REACH and REACH-2). Journal of Clinical Oncology. 38: 549-549 |